These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1466250)

  • 1. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases.
    Ebeling PR; Peterson JM; Riggs BL
    J Bone Miner Res; 1992 Nov; 7(11):1243-50. PubMed ID: 1466250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical markers of bone formation in the study of postmenopausal osteoporosis.
    Dominguez Cabrera C; Sosa Henríquez M; Traba ML; Alvarez Villafañe E; de la Piedra C
    Osteoporos Int; 1998; 8(2):147-51. PubMed ID: 9666938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The aminoterminal propeptide of type I procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects.
    Tähtelä R; Turpeinen M; Sorva R; Karonen SL
    Clin Biochem; 1997 Feb; 30(1):35-40. PubMed ID: 9056107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M; Fukunaga M; Ohtawa T; Harada T
    World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
    Hannon R; Blumsohn A; Naylor K; Eastell R
    J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of biochemical markers in patients with metabolic bone disorders.
    Hoshino H; Kushida K; Takahashi M; Kawana K; Denda M; Yamazaki K; Inoue T
    Endocr Res; 1998 Feb; 24(1):55-64. PubMed ID: 9553754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism.
    Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Artuso V; Di Virgilio R; Conte N
    Horm Metab Res; 1994 Jul; 26(7):334-7. PubMed ID: 7959610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
    Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta.
    Minisola S; Piccioni AL; Rosso R; Romagnoli E; Pacitti MT; Scarnecchia L; Mazzuoli G
    Metabolism; 1994 Oct; 43(10):1261-5. PubMed ID: 7934978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide.
    Eastell R; Rogers A; Ni X; Krege JH
    Osteoporos Int; 2011 Jun; 22(6):1927-34. PubMed ID: 20838771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reference intervals for serum concentrations of three bone turnover markers for men and women.
    Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
    Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial high serum concentrations of the carboxyl-terminal propeptide of type I procollagen.
    Sorva A; Tähtelä R; Risteli J; Risteli L; Laitinen K; Juntunen-Backman K; Sorva R
    Clin Chem; 1994 Aug; 40(8):1591-3. PubMed ID: 8045003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Relevance of Osteoclastic and Osteoblastic Activity Markers Follow-Up in Patients on Antiresorptive Osteoporosis Treatment.
    Smilic TN; Novakovic TR; Markovic-Jovanovic SR; Smilic LLJ; Mitic JS; Radunovic ML
    J Clin Densitom; 2018; 21(3):322-328. PubMed ID: 29103946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy.
    Suvanto-Luukkonen E; Risteli L; Sundström H; Penttinen J; Kauppila A; Risteli J
    Clin Chim Acta; 1997 Oct; 266(2):105-16. PubMed ID: 9437539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
    Hermus AR; Smals AG; Swinkels LM; Huysmans DA; Pieters GF; Sweep CF; Corstens FH; Kloppenborg PW
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2859-65. PubMed ID: 7559865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of bone formation by biochemical markers in metabolic bone disease: separation between osteoblastic activity at the cell and tissue level.
    Charles P; Hasling C; Risteli L; Risteli J; Mosekilde L; Eriksen EF
    Calcif Tissue Int; 1992 Dec; 51(6):406-11. PubMed ID: 1451006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum concentrations of carboxyterminal propeptide of type 1 procollogen and tissue inhibitor of metalloproteinase 1 in patients with dermatomyositis.
    Kubo M; Kikuchi K; Fujimoto M; Tamaki K
    Arch Dermatol Res; 1998 May; 290(5):253-7. PubMed ID: 9681676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women.
    Scariano JK; Glew RH; Bou-Serhal CE; Clemens JD; Garry PJ; Baumgartner RN
    Bone; 1998 Nov; 23(5):471-7. PubMed ID: 9823455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.